GlaxoSmithKline PLC ADR (GSK) - Stock & Dividends

Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US37733W2044

Vaccines, HIV medicines, Cancer medicines, Asthma medicines, Antibiotics

GSK plc is a renowned pharmaceutical company that focuses on researching, developing, and manufacturing a wide range of vaccines and medicines to prevent and treat various diseases globally.

The company operates through two main segments: Commercial Operations and Total R&D. Its vaccine portfolio includes shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines, protecting people from infectious diseases.

In addition to vaccines, GSK plc offers a diverse range of specialty and general medicines to treat various health conditions, including HIV, oncology, respiratory/immunology, and other specialty medicine products. Its inhaled medicines help alleviate asthma and chronic obstructive pulmonary disease symptoms, while its antibiotics combat infections.

GSK plc has formed strategic collaborations with CureVac to develop mRNA-based influenza vaccines and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, showcasing its commitment to innovation and advancing medical research.

With a rich history dating back to 1715, GSK plc, formerly known as GlaxoSmithKline plc, changed its name in May 2022. Headquartered in Brentford, the United Kingdom, the company continues to drive progress in the pharmaceutical industry. For more information, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for GlaxoSmithKline PLC ADR (GSK) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for GlaxoSmithKline PLC ADR (GSK) - Stock & Dividends

GSK Stock Overview

Market Cap in USD 91,286m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1986-07-09

GSK Stock Ratings

Growth 5y 26.3
Fundamental 45.4
Dividend 4.25
Rel. Performance vs Sector 0.77
Analysts 3.50/5
Fair Price Momentum 38.20 USD
Fair Price DCF 67.90 USD

GSK Dividends

Yield 12m 3.66%
Yield on Cost 5y 4.50%
Dividends CAGR 5y -7.73%
Payout Consistency 93.7%

GSK Growth Ratios

Growth 12m 15.61%
Growth Correlation 12m 69%
Growth Correlation 3m 14%
CAGR 5y 4.21%
CAGR/Mean DD 5y 0.31
Sharpe Ratio 12m 0.54
Alpha vs SP500 12m -2.91
Beta vs SP500 5y weekly 0.60
ValueRay RSI 10.70
Volatility GJR Garch 1y 19.86%
Price / SMA 50 -4.28%
Price / SMA 200 4.09%
Current Volume 3490.4k
Average Volume 20d 3674.3k

External Links for GSK Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of GSK stocks?
As of June 22, 2024, the stock is trading at USD 40.48 with a total of 3,490,372 shares traded.
Over the past week, the price has changed by -0.42%, over one month by -8.95%, over three months by -3.67% and over the past year by +19.65%.
What are the forecast for GSK stock price target?
According to ValueRays Forecast Model, GSK GlaxoSmithKline PLC ADR will be worth about 41.8 in June 2025. The stock is currently trading at 40.48. This means that the stock has a potential upside of +3.29%.
Issuer Forecast Upside
Wallstreet Target Price 46.5 14.9
Analysts Target Price 39.6 -2.10
ValueRay Target Price 41.8 3.29

GlaxoSmithKline PLC (GSK): A Comprehensive Overview

History of GlaxoSmithKline PLC (GSK)

GlaxoSmithKline PLC, commonly known as GSK, is a British multinational pharmaceutical company with a rich history that dates back to the 18th century. The modern incarnation of GSK was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, but its roots can be traced to a small apothecary in London in 1715. Over the centuries, the company has been at the forefront of medical innovation, developing and distributing pharmaceuticals, vaccines, and health-related consumer products worldwide.

Core Business of GSK

GSK's core business revolves around the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. In pharmaceuticals, the company has a strong focus on immunology, oncology, and infectious diseases. The vaccine division of GSK is one of the largest in the world, providing vaccines for a multitude of diseases such as influenza, hepatitis, and rotavirus. Additionally, GSK's consumer healthcare segment offers a range of oral health, pain relief, respiratory, and nutritional products aimed at improving the quality of human life.

Side Businesses and Other Ventures

Besides its main pharmaceutical, vaccine, and consumer healthcare products, GSK is also involved in several side businesses and ventures. This includes partnerships with other pharmaceutical companies for research and development efforts, involvement in philanthropy through the GSK Foundation, and investment in biotechnology startups. The company's strategic focus on innovation and collaboration extends beyond traditional boundaries, aiming to address unmet medical needs and foster a healthier global community.

Current Market Status

As of the current market status, GSK remains a leading entity in the pharmaceutical industry, continually adapting to meet global health challenges. Despite facing competition, regulatory pressures, and the complexities of patent cliffs, GSK has maintained a solid market presence. The company's dedication to research and development has been pivotal in driving growth, with a strong pipeline of products anticipated to contribute to its future success. GSK's shares are actively traded on the New York Stock Exchange (NYSE) under the ticker GSK, where it is closely watched by investors for its performance, innovation, and resilience in the ever-changing pharmaceutical landscape.